{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:22:03Z","timestamp":1761988923729,"version":"3.37.3"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"8","funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Infect Dis."],"published-print":{"date-parts":[[2016,4,15]]},"DOI":"10.1093\/cid\/civ1213","type":"journal-article","created":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T20:09:10Z","timestamp":1452542950000},"page":"972-979","source":"Crossref","is-referenced-by-count":32,"title":["Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir\/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors"],"prefix":"10.1093","volume":"62","author":[{"given":"Amit","family":"Khatri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Podsadecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walid","family":"Awni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev","family":"Menon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,1,5]]},"reference":[{"key":"2016032209142207000_62.8.972.1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http:\/\/aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf . Accessed 14 October 2014."},{"key":"2016032209142207000_62.8.972.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.8722"},{"key":"2016032209142207000_62.8.972.3","unstructured":"European AIDS Clinical Society. European AIDS clinical society guidelines, version 7.1. Brussels, Belgium: European AIDS Clinical Society, 2014."},{"key":"2016032209142207000_62.8.972.4","unstructured":"World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva, Switzerland: World Health Organization, 2013."},{"key":"2016032209142207000_62.8.972.5","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics3040745"},{"key":"2016032209142207000_62.8.972.6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.045"},{"key":"2016032209142207000_62.8.972.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402338"},{"key":"2016032209142207000_62.8.972.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402869"},{"key":"2016032209142207000_62.8.972.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315722"},{"key":"2016032209142207000_62.8.972.10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.1328"},{"key":"2016032209142207000_62.8.972.11","unstructured":"Khatri A , Wang H , Wang T et al . Drug-drug interactions of the direct acting antiviral regimen of ABT-450\/r, ombitasvir and dasabuvir with HIV protease inhibitors. Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 5\u20139 September 2014; Washington, DC."},{"key":"2016032209142207000_62.8.972.12","unstructured":"Center for Drug Evaluation and Research (CDER). Application number: 206619Orig1s000 summary review for regulatory action. Rockville, MD: Food and Drug Administration, 2014. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/206619Orig1s000SumR.pdf. Accessed 27 January 2016."},{"key":"2016032209142207000_62.8.972.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.01.026"},{"key":"2016032209142207000_62.8.972.14","first-page":"91A","article-title":"Treatment-na\u00efve, HCV genotype 1-infected subjects show significantly greater HCV RNA decreases when treated with 28 days of ABT-333 plus peginterferon and ribavirin compared to peginterferon and ribavirin alone","volume":"50","author":"Rodriguez-Torres","year":"2009","journal-title":"Hepatology"},{"key":"2016032209142207000_62.8.972.15","unstructured":"Gaultier IA , Cohen DE , Dumas EO , Larsen LM , Podsadecki TJ , Bernstein B . 12-Week efficacy and safety of ABT-072 or ABT-333 with pegylated interferon + ribavirin, following 3-day monotherapy in genotype 1 HCV-infected treatment-na\u00efve subjects. Presented at: 21st Conference of the Asian Pacific Association for the Study of the Liver; 17\u201320 February 2011; Bangkok, Thailand."},{"key":"2016032209142207000_62.8.972.16","doi-asserted-by":"crossref","first-page":"S480","DOI":"10.1016\/S0168-8278(12)61222-7","article-title":"ABT-267 combined with pegylated interferon alpha-2a\/ribavirin in genotype 1 (GT1) HCV-infected treatment-naive subjects: 12 week antiviral and safety analysis","volume":"56","author":"Sullivan","year":"2012","journal-title":"J Hepatology"},{"key":"2016032209142207000_62.8.972.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208809"},{"key":"2016032209142207000_62.8.972.18","doi-asserted-by":"crossref","first-page":"S484","DOI":"10.1016\/S0168-8278(13)61191-5","article-title":"Study of ABT-267 2-day monotherapy followed by 12-week combination therapy in treatment-naive patients with chronic HCV genotype 1 infection","volume":"58","author":"Epstein","year":"2013","journal-title":"J Hepatol"},{"key":"2016032209142207000_62.8.972.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306227"},{"key":"2016032209142207000_62.8.972.20","unstructured":"Sekar V , De Paepe E , Van Baelen B et al . Pharmacokinetic\/pharmacodynamic (PK\/PD) analyses of darunavir in the TITAN study. Presented at: 11th Annual European AIDS Conference; 24\u201327 October 2014, 2007; Madrid, Spain."},{"key":"2016032209142207000_62.8.972.21","unstructured":"Sekar V , Vanden Abeele C , Van Baelen B et al . Pharmacokinetic-pharmacodynamic analyses of once-daily darunavir in the ARTEMIS study. Presented at: 15th Annual Conference on Retroviruses and Opportunistic Infection; 3\u20136 February 2008; Boston, Massachusetts."},{"key":"2016032209142207000_62.8.972.22","doi-asserted-by":"publisher","DOI":"10.1186\/1758-2652-13-S4-P185"},{"key":"2016032209142207000_62.8.972.23","doi-asserted-by":"crossref","unstructured":"Molto J , Valle M , Ferrer E et al . Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients. Presented at: 15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy; 19 May 2014; Washington, DC.","DOI":"10.1093\/jac\/dku516"},{"key":"2016032209142207000_62.8.972.24","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Drug interaction studies\u2014study design, data analysis, implications for dosing, and labeling recommendations. Rockville, MD: Food and Drug Administration, 2012."},{"key":"2016032209142207000_62.8.972.25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1128\/AAC.01778-15","article-title":"Drug interactions with the direct-acting antiviral combination of ombitasvir and paritaprevir\/ritonavir (2D regimen)","volume":"60","author":"Badri","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2016032209142207000_62.8.972.26","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-014-9379-8"},{"key":"2016032209142207000_62.8.972.27","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-015-9846-1"},{"key":"2016032209142207000_62.8.972.28","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry. Drug-induced liver injury: premarketing clinical evaluation. Rockville, MD: Food and Drug Administration, 2009."},{"key":"2016032209142207000_62.8.972.29","unstructured":"Reyataz (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb, 2014."},{"key":"2016032209142207000_62.8.972.30","unstructured":"Ruane P , Adeyemi O , Trinh R et al . TURQUOISE-I study: use of ombitasvir\/paritaprevir\/ritonavir + dasabuvir + ribavirin in patients with HCV\/HIV-1 co-infection on stable darunavir-containing antiretroviral therapy. Presented at: 15th European AIDS Conference; 21\u201324 October 2015; Barcelona, Spain."}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/62\/8\/972\/7450606\/civ1213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T09:13:04Z","timestamp":1503565984000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/civ1213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,5]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,3,22]]},"published-print":{"date-parts":[[2016,4,15]]}},"alternative-id":["10.1093\/cid\/civ1213"],"URL":"https:\/\/doi.org\/10.1093\/cid\/civ1213","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"type":"print","value":"1058-4838"},{"type":"electronic","value":"1537-6591"}],"subject":[],"published":{"date-parts":[[2016,1,5]]}}}